Oppenheimer analyst Jay Olson reiterated an Outperform rating and $21 price target on Sky Bioscience after meeting with the company’s management to discuss strategic objectives and upcoming catalysts. The firm said it anticipates body composition to become an important endpoint in obesity clinical trials, noting that management plans to initiate a Phase 2 study for nimacimab in Q3 followed by an interim readout in Q1. Oeppnehimer views Skye as financially well-positioned with $83.3M cash providing expected runway into 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience Files Current SEC Report
- Skye Bioscience focuses clinical development on nimacimab metabolic program
- Skye Bioscience to discontinue clinical development related to SBI-100 OE
- Skye Bioscience says Phase 2a trial of SBI-100 OE did not meet primary endpoint
- Skye Bioscience to Present at Jefferies Global Healthcare Conference